U.S. markets closed
  • S&P 500

    4,136.48
    -43.28 (-1.04%)
     
  • Dow 30

    33,926.01
    -127.93 (-0.38%)
     
  • Nasdaq

    12,006.96
    -193.86 (-1.59%)
     
  • Russell 2000

    1,985.53
    -15.69 (-0.78%)
     
  • Crude Oil

    73.23
    -2.65 (-3.49%)
     
  • Gold

    1,865.90
    -50.40 (-2.63%)
     
  • Silver

    22.40
    -1.22 (-5.17%)
     
  • EUR/USD

    1.0798
    -0.0113 (-1.04%)
     
  • 10-Yr Bond

    3.5320
    +0.1360 (+4.00%)
     
  • GBP/USD

    1.2056
    -0.0173 (-1.41%)
     
  • USD/JPY

    131.1500
    +2.5460 (+1.98%)
     
  • BTC-USD

    23,307.16
    -123.65 (-0.53%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19

  • NanoViricides Inc (NYSE: NNVC) has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections.

  • The treatment candidate was well tolerated in safety pharmacology studies in both rat and non-human primate models. Multiple injections of NV-CoV-2 were also well-tolerated in an extensive non-GLP study in rats performed by AR Biosystems Inc.

  • The studies showed that intravenous (IV) administration of NV-CoV-2 at doses of 25, 50, and 100 mg/kg did not affect rats' respiratory function. IV infusion at 25, 37.5, and 50 mg/kg did not have any toxicologic effects on cardiac rhythm or ECG morphology in cynomolgus monkeys. No significant effects on blood pressure and heart rate were observed.

  • Pre-IND application submission to the US FDA is up next to obtain guidance regarding human clinical trials.

  • Price Action: NNVC gained 6.8% at $5.03 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.